Novo Nordisk (NVO): Q4 EPS of DKK10.53 beats by DKK0.77. Q4 EBIT +25% to DKK7.57B. Net profit...

|About: Novo Nordisk A/S (NVO)|By:, SA News Editor
Novo Nordisk (NVO): Q4 EPS of DKK10.53 beats by DKK0.77. Q4 EBIT +25% to DKK7.57B. Net profit +23% to DKK5.75B. Sales +16% to DKK20.96B. Sales of diabetes drug was driven by Victoza +29%, modern insulins +20%, NovoSeven +20%. Expects FY13 sales growth to be 8-11%, Operating profit growth to be approx. 10%. (PR)